The Franco-Austrian pharmaceutical group announced in a press release that it will raise 103 million euros to finance its vaccine programs against Lyme disease and the chikungunya virus.
The Franco-Austrian laboratory Valneva announced this Friday to increase its capital by 102.9 million euros through the issuance of 21 million ordinary shares in the United States and Europe, to finance the development of its vaccines against Lyme disease and against the virus. chikungunya.
“Due to strong demand, the company has increased the size of the issue, initially forecast at $40 million,” Valneva said in a press release, adding that “the total gross amount is expected to increase by approximately $102, 9 million euros, which is equivalent to approximately 99.9 million dollars”.
>> More information to come on BFM Business in a few moments. You can also watch BFM Business live on video and Follow us on Twitter.
Source: BFM TV
